Year-end Sale % OFF 
Abstract
Background Gastric cancer (GC) has a poor prognosis due to the lack of ideal tumor markers. Circular RNAs (circRNAs) are a novel type of noncoding RNA related to the occurrence of GC. Among our research, we investigated the role of hsa_circ_0005556 in GC. Materials and Methods The expression of hsa_circ_0005556 of 100 paired GC tissues and adjacent normal tissues was detected using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). A receiver operating characteristic (ROC) curve was established to evaluate the diagnostic value of hsa_circ_0005556. The correlation between the expression of hsa_circ_0005556 and corresponding clinicopathological characteristic was explored. Results hsa_circ_0005556 was significantly downregulated in GC tissues contrasted with adjacent normal tissues (n = 100, p < 0.001). The areas under the ROC curve (AUC) of hsa_circ_0005556 were up to 0.773, while 64% sensitivity and 82% specificity, respectively. Moreover, its expression levels were significantly associated with differentiation (p = 0.001), TNM stage (p = 0.013), and lymphatic metastasis (p = 0.039). GC patients of high hsa_circ_0005556 levels had a longer overall survival (OS) than those of the low group (p = 0.047). Conclusion hsa_circ_0005556 is a potential biomarker for GC, which may guide judgment of the indication of endoscopic treatment for early gastric cancer (EGC).
Highlights
Gastric cancer (GC), a serious global health risks, ranks as the fifth most common cancer and the third primary cause of cancer-related death globally
To detect the expression of hsa_circ_0005556 in GC tissues, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used in 100 pairs of GC and adjacent normal samples
The results indicated that hsa_circ_ 0005556 was significantly downregulated in GC tissues contrast to adjacent normal tissues (n = 100, p < 0:001, Figures 2(a) and 2(b))
Summary
Gastric cancer (GC), a serious global health risks, ranks as the fifth most common cancer and the third primary cause of cancer-related death globally. The 5-year survival rate of stage I patients can reach 90%, while that of the stage IV patients who already show distant metastases is only approximately 14% [2]. Most patients with early gastric cancer (EGC) have no obvious specific symptoms [3]. The 5-year survival rate of GC is an average of 20-40% [5]. A receiver operating characteristic (ROC) curve was established to evaluate the diagnostic value of hsa_circ_0005556. Hsa_circ_0005556 was significantly downregulated in GC tissues contrasted with adjacent normal tissues (n = 100, p < 0:001). GC patients of high hsa_circ_0005556 levels had a longer overall survival (OS) than those of the low group (p = 0:047). Hsa_circ_0005556 is a potential biomarker for GC, which may guide judgment of the indication of endoscopic treatment for early gastric cancer (EGC) Conclusion. hsa_circ_0005556 is a potential biomarker for GC, which may guide judgment of the indication of endoscopic treatment for early gastric cancer (EGC)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
